Shattuck Labs (NASDAQ:STTK) Rating Lowered to Neutral at BTIG Research

Shattuck Labs (NASDAQ:STTKGet Free Report) was downgraded by stock analysts at BTIG Research from a “buy” rating to a “neutral” rating in a report issued on Monday, MarketBeat Ratings reports.

STTK has been the topic of several other reports. Needham & Company LLC dropped their target price on Shattuck Labs from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, June 14th. HC Wainwright reiterated a “buy” rating and set a $28.00 target price on shares of Shattuck Labs in a report on Wednesday, May 15th.

View Our Latest Stock Analysis on Shattuck Labs

Shattuck Labs Trading Down 7.8 %

NASDAQ STTK opened at $4.59 on Monday. The business’s 50-day moving average price is $8.59 and its 200 day moving average price is $8.35. Shattuck Labs has a twelve month low of $1.33 and a twelve month high of $11.76. The company has a market capitalization of $218.26 million, a PE ratio of -2.38 and a beta of 1.85.

Shattuck Labs (NASDAQ:STTKGet Free Report) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.08. The company had revenue of $1.15 million for the quarter, compared to the consensus estimate of $0.30 million. Shattuck Labs had a negative return on equity of 64.85% and a negative net margin of 3,133.63%. Shattuck Labs’s revenue for the quarter was up 2200.0% on a year-over-year basis. Equities analysts predict that Shattuck Labs will post -1.56 EPS for the current year.

Institutional Investors Weigh In On Shattuck Labs

Hedge funds have recently bought and sold shares of the business. Cannon Global Investment Management LLC acquired a new stake in Shattuck Labs during the 1st quarter valued at approximately $91,000. Tower Research Capital LLC TRC grew its stake in Shattuck Labs by 79.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 13,553 shares of the company’s stock valued at $97,000 after purchasing an additional 5,989 shares in the last quarter. Virtu Financial LLC acquired a new stake in Shattuck Labs during the 1st quarter valued at approximately $113,000. Reliant Investment Management LLC acquired a new stake in Shattuck Labs during the 4th quarter valued at approximately $143,000. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in Shattuck Labs during the 1st quarter valued at approximately $174,000. Institutional investors and hedge funds own 58.74% of the company’s stock.

Shattuck Labs Company Profile

(Get Free Report)

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.

Read More

Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.